Compare ConocoPhillips (COP) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Gilead Sciences, Inc. — how do they compare? ConocoPhillips trades at $133.54 (market cap $155.98B), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and ConocoPhillips pays the higher dividend (2.59%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Gilead Sciences, Inc. for 111 Days on average.
| COP | GILD | |
|---|---|---|
Market Cap | $155.98B | $182.09B |
Volume | 4,774,951 | 4,960,247 |
Sector | Energy | Health |
52-Week High | $141.22 | $155.80 |
52-Week Low | $85.66 | $116.74 |
Typical Hold Time | 79 Days | 111 Days |
Enterprise Value | $171.58B | $205.15B |
Dividend Yield | 2.59% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.19, up 3.74% with strong technical momentum and bullish moving averages. The company shows solid fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global announced October 1, 2026. Valuation metrics remain reasonable with P/E of 17.17 and EV/EBITDA of 6.17, while analyst consensus favors Buy ratings (75%) with a $154.75 price target.
Outlook remains positive given robust cash flow generation and strategic LNG expansion, though risks include oil price volatility and geopolitical exposure. The stock offers value with upside potential to analyst targets, but investors should monitor execution on international asset sales and energy market dynamics.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
